cimetidine has been researched along with Hyperlipoproteinemia Type II in 1 studies
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.
Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calero, M | 1 |
| Escobar, M | 1 |
| Sampalo, A | 1 |
| Senra, A | 1 |
| Zamora, E | 1 |
| Millán, J | 1 |
1 other study available for cimetidine and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
[The hypolipemic effect of cimetidine].
Topics: Adult; Aged; Cimetidine; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Hyperlip | 1990 |